Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests.